I think you're about to be undressed in public. Too close to earnings (which figure to be neither a positive nor a negative for stock price this time around) and too close to likely positive announcement to go making such predictions. Also, the next CC will be the third since the terrible one, which is about the long-term memory of portfolio managers (or their liaisons with the staff analysts)
Disorderly market today with gold plummeting. There's a psychologically important level not far below the present price (I'd call it $1200/ozt). But generally, big gold investors and big biotech investors are different people, so over an investing timespan a gold rout ought to affect INCY less than it affects a lot of other stocks.
Something that may be having an effect today, but shouldn't in the long run, is the ACLU/Myriad case on gene patents before SCOTUS. Court watchers are predicting a narrow ruling that leaves the value of Incyte's gene patents in doubt. Since nobody attached significant value to them last week (when their value was in doubt), nobody is likely to think their value has decreased much if a decision leaves their value in doubt. But an idiot bear (actually, less common than idiot bulls) might well be reflexively shorting the owner of the most gene patents (Incyte) today.